CATAPULT GROUP INTERNATIONAL LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT

CAT - CATAPULT GROUP INTERNATIONAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 2.06
Index: ASX300 | ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.28

14 May
2025

-0.090

OPEN

$4.45

-2.06%

HIGH

$4.51

1,192,680

LOW

$4.23

TARGET
$4.70

+0.20 change from previous day

 9.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 7.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201820192021202220232024
EPS Basic xxxxxxxxxxxxxxx-10.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx152.1 M
Book Value Per Share xxxxxxxxxxxxxxx48.3
Net Operating Cash Flow xxxxxxxxxxxxxxx45.4 M
Net Profit Margin xxxxxxxxxxxxxxx-16.68 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-20.36 %
Return on Invested Capital xxxxxxxxxxxxxxx-16.77 %
Return on Assets xxxxxxxxxxxxxxx-10.23 %
Return on Equity xxxxxxxxxxxxxxx-20.36 %
Return on Total Capital xxxxxxxxxxxxxxx-15.10 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx29.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx27 M
Total Debt xxxxxxxxxxxxxxx28 M
Goodwill - Gross xxxxxxxxxxxxxxx79 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx3.21

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192021202220232024
Capex xxxxxxxxxxxxxxx41.1 M
Capex % of Sales xxxxxxxxxxxxxxx27.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx148 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx27 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

13/05/2025

1

Initiation of coverage with Buy

$5.00

16.82%

UBS has initiated coverage of Catapult International with a Buy rating and $5 price target, suggesting there is upside potential on the proviso growth forecasts can be achieved.

Assuming forecasts will be met, the broker is projecting a cash EBITDA of US$41m (A$63m) by FY28, which is EBITDA minus capex.

The broker also points out Catapult is to become a member of the ASX Technology Rule of 40 club, implying the shares should --at a minimum-- trade on 25x times EV/Cash EBITDA.

UBS's current valuation is derived from a combination of DCF and EV/Cash EBITDA. 

The investment thesis sees earnings growth being underpinned by the delivery of 20% p.a. recurring revenue growth alongside circa 50% incremental Cash EBITDA margins.

Current forecasts still imply two more years of losses (FY25 and FY26).

FORECAST
UBS forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -7.69 cents.
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.08 cents.

Morgan Stanley

xx/xx/xxxx

-1

xx xxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

31/03/2025

1

Buy

$4.20

-1.87%

Canaccord Genuity lifted the target price on Catapult International to $4.20 from $3.50 after the company's investor day boosted its confidence in the long-term strategy and long-term margin assumptions.

The company is eyeing a 10-fold increase in Annual Contract Value to US$1bn and a medium-term strategy to increase wearable teams to 5k from 3.5k currently.

Buy rating unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -6.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.61 cents.
Access Extra Coverage Research History >

CAT STOCK CHART

FNArena News on CAT

1
Australian Broker Call *Extra* Edition – Mar 31, 2025

Mar 31 2025 - Daily Market Reports
2
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
3
November In Review: Valuation Concern Trumped

Dec 04 2024 - Australia
4
Australian Broker Call *Extra* Edition – Nov 19, 2024

Nov 19 2024 - Daily Market Reports
5
FNArena Corporate Results Monitor – 15-11-2024

Nov 15 2024 - Australia

Latest Medical Equipment & Devices News

1
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
2
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
3
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
4
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
5
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
6
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
7
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
8
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
9
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
10
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals